Note: this report is one of two complaints that pertain to the same event and same patient (mfr report (b)(4).It was reported to boston scientific that two advanix biliary stents were successfully placed as stent exchange during an endoscopic retrograde cholangiopancreatography (ercp) procedure in the common bile duct, performed on (b)(6) 2023.From (b)(6) 2023, at an outside hospital (osh), the patient experienced acute right upper quadrant (ruq) pain, emesis (vomiting), chills and fever of 100.7 degrees, concerning for cholangitis.The patient was hospitalized and was given levofloxacin, metronidazole, flagyl, dapto, and tylenol as a treatment for cholangitis, fever, and pain; and was also administered with intravenous lactated ringer's (lr) solution for hydration.From (b)(6) 2023, it was reported that the cholangitis was growing and was vancomycin-resistant enterococci complicated by sepsis, and post ercp pancreatitis with hepatic abscess due to the procedure performed on (b)(6) 2023.From (b)(6) 2023, the patient experienced abdominal pain in the setting of transaminitis with obstruction.The patient was discharged with ceftriaxone and metronidazole as discharged medication.The fever seemed to be better at the time the patient was discharged.On (b)(6) 2023, another procedure was performed to remove the implanted stents (the subject of this report (b)(4), and a wallflex biliary stent was placed to successfully complete the procedure.The patient was reported to have pancreatic cancer and pain was ongoing.In the physician's assessment, there was a chance that the patient's adverse event was due to the stent change and the cholangitis was concerning for sepsis.
|
Block a2: patient's exact age is unknown; however, it was reported that the patient's year of birth was 1945.Block d4, h4: the complainant was unable to provide the suspect device lot number; therefore, the lot expiration and device manufacture dates are unknown.Block g2: study: e7118 boston scientific corporation endoscopy post market surveillance data collection.Block h6: imdrf patient code (b)(6) captures the reportable event of cholangitis.Imdrf patient code (b)(6) captures the reportable event of abscess.Imdrf patient code (b)(6) captures the reportable event of sepsis.Imdrf patient code (b)(6) captures the reportable event of pain.Imdrf impact code (b)(6) captures the reportable event of unexpected medical intervention.Imdrf impact code (b)(6) captures the reportable event of medication required.Imdrf impact code (b)(6) is being used to capture the reportable event of hospitalization or prolonged hospitalization.
|